MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » AngioDynamics’ Q1 sales rise, profits slump | Wall Street Beat

AngioDynamics’ Q1 sales rise, profits slump | Wall Street Beat

By

AngioDynamics

AngioDynamics (NSDQ:ANGO) saw its first-quarter profits slump despite posting a 5.7 percent top-line increase during the three months ended August 31.

The Albany, N.Y.-based medical device maker reported net income of $1.4 million, or 5 cents per share, on sales of $54.4 million for the quarter. That compares with profits of $1.9 million, or 8 cents EPS, on sales of $51.5 million during the same period last year.

"Our team generated solid first quarter results and achieved the guidance they provided in July," new president & CEO Joseph DeVivo said in prepared remarks. "Since joining the company, I have been spending time getting to know the organization and see many positive attributes. We have two strong U.S. sales organizations and a very professional international team driving above-market growth. At the same time, key opinion leaders have confirmed to me the significant opportunity ahead for the NanoKnife System. In addition, we are committed to a balanced approach to managing our cash. Our top priority is acquiring tuck-in technologies that can leverage our sales forces, are synergistic to the core business and complement our organic growth. Also, we will initiate a stock repurchase program to use some of the free cash flow generated in fiscal 2012."

Sign up to get our free newsletters delivered right to your inbox

AngioDynamics said it expects sales of between $55.5 million and $57.5 million during the second quarter and full-year sales of between $217.0 million and $225.0 million. Second-quarter earnings are expected to be 9 cents to 11 cents, with full-year EPS ranging between 33 cents and 41 cents.

The company also said its board OK’d a stock buyback plan that could see it repurchase up to $20 million worth of shares before May 31, 2012.

KCI sets shareholders meeting to approve Apax buyout
Kinetic Concepts Inc. (NYSE:KCI) is planning a shareholders’ meeting Oct. 28 for a vote on Apax Partners’ $6.3 billion offer to take the wound care company private.

The meeting, slated to be held in San Antonio, will see KCI’s investors decide whether to accept the $68.50-per-share leveraged buyout, now that a bid by rival ConvaTec is officially dead and the financial terms settled.

Apax and a pair of Canadian pension funds agreed July 12 to buy KCI for $68.50 per share. The London-based private equity firm and its partners plan to finance the buyout with about $5 billion in debt, backed by lenders Bank of America Corp., Credit Suisse Group AG and Morgan Stanley.

If approved, the deal is expected to close in November. Read more

Citigroup lowers Abbott price target
Citigroup (NYSE:C) cut its price target for Abbott Laboratories (NYSE:ABT) price target from $50 to $46.

The move comes a week after researchers at JP Morgan Chase & Co. downgraded ABT shares from "overweight" to "neutral." Read more

Angeion buys back $2.8M worth of shares

Angeion Corp. (NSDQ:ANGN) spent more than $2.8 million buying back shares of its own stock, according to a filing with the federal Securities & Exchange Commission.

The St. Paul-based cardiac diagnostic systems maker said it repurchased 12,000 shares in September.

Angeion slipped into the red during the third quarter, reversing a $136,000 profit into an $81,000 loss for the three months ended July 31, blaming legal fees and severance payouts to former CEO Philip Smith, whom the company sacked after just five months on the job. Read more

Cardiovascular Systems predicts Q1 sales growth, narrower losses
Cardiovascular Systems Inc. (NSDQ:CSII) said it expects to post sales growth of about 2 percent and narrower net losses for its fiscal first quarter.

The St. Paul-based peripheral artery disease firm posted its preliminary Q1 results, saying sales should reach $18.7 million for the three months ended Sept. 30, compared with $18.2 million during the same period last year.

Net losses are expected to range between $3.9 million and $4.2 million, down from the $4.3 million loss posted during fiscal 2011’s first quarter.

"After five consecutive quarters of double-digit revenue growth, CSI’s growth slowed in the fiscal 2012 first quarter and was below our guidance. While we are still reviewing the results, we believe several factors disrupted growth in the short-term, but will lead to higher revenue growth in the future," president & CEO David Martin said in prepared remarks. Read more

In case you missed it

RSS From Medical Design & Outsourcing

  • Bringing motion to medicine: How Actuated Medical is innovating deep brain stimulation and more
    Actuated Medical is making electrode placement for deep brain stimulation easier and less traumatic. Nearly 16 years ago, Actuated Medical co-founder, President and CEO Maureen Mulvihill was working for a company making actuators that were the size of a grain of rice. While the company was focused on components, she wanted to help patients more.… […]
  • Elkem Silicones opens new medical silicone production facility
    Elkem Silicones announced today that it opened its new specialized facility for producing high-purity medical silicones. York, South Carolina-based Elkem held a grand opening on Sept. 28. Customers and local, state and federal officials attended the event, which featured a ribbon-cutting ceremony, facility tours and a reception. “Elkem’s investment in this highly specialized facility demonstrates… […]
  • Three considerations for reshoring your medical device components and assemblies
    Reshoring medical devices — moving production back to the United States — requires strategic and complex navigation. John Banks and Richard Landry, Beacon MedTech Solutions Reshoring is a topic of conversation with almost every biopharma, life sciences and medical company currently outsourcing production of thermoplastic or silicone parts, products and assemblies to overseas molders. Just… […]
  • How Medline maintains quality while innovating and growing
    Medline President of Quality and Regulatory Affairs Lara Simmons offers insight into innovation and quality as the company grows. When Lara Simmons joined Medline Industries in 1991, she began by performing packaging validations. At the time, Medline was bringing in $250 million in sales per year, and the company’s quality assurance team had only about… […]
  • How this inside-out vascular access system simplifies catheter placement
    Bluegrass Vascular Technologies is making catheter placement procedures for dialysis and chemotherapy easier and safer using inside-out technology, explains CEO and President Gabi Niederauer. Bluegrass Vascular Technologies has figured out a way to make a catheter sheath go inside the body and back out for easy catheter placement in standard access procedures. The San Antonio,… […]
  • 6 Steps for Winning at Life Sciences Bid Management
    By Bob Steller, Industry Principal – Life Sciences Discover the secret to success for planning, executing—and winning—profitable bids Did you know that 85% of revenue in the medical technology market comes through bids and tenders? For Life Sciences companies like yours, one key to building and expanding your business is mastering the art and science… […]
  • Digital Pump Customization: Unlocking the True Potential of BLDC Motors
    By using advanced electric motors, a variety of motor and pump parameters can be customized to individual customer needs. It is becoming increasingly more valuable to be able to monitor all electronic components on board medical devices. By taking advantage of the full capabilities and digital customization of brushless direct current (BLDC) motor controllers, pumps… […]
  • Why Automate? Justification and Impact Explained
    Do you want to integrate automation into your manufacturing process but you’re unsure where to start? Maybe your biggest hurdle is justifying the costs associated with the change. Effectively communicating the reasons why and the ROI to all stakeholders in this major shift is a necessary starting point. Justifying the Need to Automate Increased production… […]
  • In vivo electroporation is an engineering solution for drug and gene delivery
    Why the new buzz about an old technique? Harness the potential of an existing technology for modern medicine. Daniel Friedrichs, Minnetronix Medical Reversible electroporation is the use of an electric field to open pores in a cell wall, allowing transport of drugs, DNA or other “cargo” into a cell — in particular, allowing delivery of… […]
  • FDA and VA Ventures Innovation Institute partner on new medical device testing tools
    The Department of Veterans Affairs’ VA Ventures Innovation Institute in Seattle will host up to a dozen FDA staffers in a new collaboration to develop and share new tools for medical device testing safety and efficacy. The agencies intend to provide developers of devices and new technology with off-the-shelf tools that can help streamline regulatory… […]
  • How Boston Scientific is managing labor shortages with cobots and Spanish
    Boston Scientific (NYSE: BSX) executives said two labor-shortage strategies are paying off in a big way for the medical device maker, which has around 41,000 employees across the globe. Collaborative robotics and Spanish-speaking shifts are helping Boston Scientific deal with labor shortages in the U.S. and elsewhere. That’s according to Global Operations EVP Brad Sorenson… […]

Leave a Reply